Curriculum vitae Ad personam

Prof. Wolfgang Wick, MD Medical Director, Neurology Clinic INF 400, D-69120 Heidelberg Phone: 06221-567075 Fax: 06221-567554 E-Mail: neuroonkologie@med.uni-heidelberg.de married to Antje Wick, MD two children

Major clinical interests:

Primary brain tumors (glioma and lymphoma) Metastatic brain tumors Neurological complications of cancer Neuroimmunology (multiple sclerosis, other neurological autoimmune

disease) → Neurooncology ward and outpatient clinic, Headclinic Heidelberg Major research interests:

Clinical trials Targeted antiangiogenic therapies Prognostic and predictive biomarkers Immunotherapy

→ Study center at the NCT and outpatient clinics; Clinical Cooperation Unit Neurooncology, German Cancer Research Center, Heidelberg

Education

09/80 – 05/89 Carl-von-Ossietzky Gymnasium, Bonn 06/89 – 09/90 Civil service: St. Marienhospital Bonn 10/90 – 08/93 University of Bonn: Medicine 09/93 – 06/94 King´s College London, Great Britain 07/94 – 08/96 University of Bonn 09/96 – 05/97 Harvard Medical School, Boston, USA 06/97 – 11/97 University of Bonn 11/97 Examination 05/98 Doctoral thesis at the Institute for Neuropathology (Prof. Dr.

O.D. Wiestler) at the University of Bonn (Summa cum laude) Appointments 01/98 – 06/99 Internship at the Department of Neurology, University of

Tübingen (Chairman: Prof. Dr. J. Dichgans)

2

07/99 – 12/01 Resident at the Department of Neurology, University of Tübingen 01/02 – 12/02 Resident at the Department of Psychiatry, University of Tübingen

(Chairman: Prof. Dr. G. Buchkremer) 04/03 Board certification in Neurology 07/03 Habilitation and venia legendi for Neurology 08/03 – 10/08 Head of the Research Group Hematopoietic stem cells and

glioma of the State of Baden-Württemberg since 08/04 Attending in Neurology since 10/2005 Steering Committee of the Brain Tumor Group of the EORTC 04-12/06 Vice Chairman, Dep. of General Neurology, University of

Tübingen, Germany (Chairman: Prof. Dr. M. Weller) 01/07 – 09/14 Chairman Dep. of Neurooncology/NCT and Professor of Clinical

Neurooncology, University of Heidelberg since 07/2007 Steering Committee of the Neurooncology Working Group (NOA)

of the German Cancer Society 02/2008-02/2009 Chair-elect of the Brain Tumor Group of the EORTC 09/2008 Member of the EANO Board 03/2009 Chairman of the EORTC Brain Tumor Group 03/2009 Member of the of the Grant Application Council for Young

Scientists of the German Cancer Aid 01/2010 Member of the Board of Directors at the NCT 01/2010-04/2014 06/2014 10/2014

Member of the Board of Directors European Cancer Organization (ECCO) Chair of the NOA Chairman General Neurology Heidelberg

Publications

since 1998 >250 peer-reviewed publications http://www.ncbi.nlm.nih.gov/sites/entrez/wick w e.g. Annals of Neurology, Brain, Cancer Research, Journal of Clinical Investigation, Journal of Clinical Oncology, The Lancet Oncology, The New England Journal of Medicine, Nature, Nature Medicine, Neurology, and Neurooncology

Scholarships and awards

1991 – 1997 Scholar of the German National Scholarship Foundation 1993 - 1994 Grant of the German National Scholarship Foundation for the

studies in London, UK 1996 - 1997 Grant of the German National Scholarship Foundation for the

studies in Boston, USA 1996 Grant of the Boehringer Ingelheim Fonds 1997 Best doctoral thesis of the Medical Faculty at the University of

Bonn 2001 Attempto-Award for Neurobiology of the University of Tübingen 2003 Novartis-Award for Clinical Research 2005 Sibylle-Assmus Award for Neurooncology 2006 Pette Award of the German Society of Neurology

3

2009 Key Note Lecture World Federation of Neurooncology Meeting, Japan

Fellow of the Faculty of the 1000 Medicine Memberships American Society of Clinical Oncology (ASCO); Deutsche

Gesellschaft für Neurologie; Deutsche Gesellschaft für Gentherapie; Neuro-Onkologische Arbeitsgemeinschaft (NOA) der Deutschen Krebsgesellschaft (DKG); Deutsche Krebshilfe, European Association of Neuro Oncology (EANO); Faculty of the European Society of Medical Oncology (ESMO); Steering Committee of the Brain Tumor Group of the European Organisation for Research and Treatment of Cancer (EORTC)

Ad hoc referee American Journal of Pathology; Brain; Brain Research; British

Journal of Cancer; Cancer Investigation; Cancer Letters; Cancer Research; Cellular Physiology and Biochemistry; Clinical Cancer Research; Critical Reviews in Oncology/Hematology; European Journal of Cancer; Experimental Neurology, Glia; International Journal of Cancer; Journal of Neurochemistry; Leukemia; Microscopy Research and Technique; Neurology; Neurooncology; Oncogene; Pharmacology & Therapeutics; Targeted Oncology; Therapy; The Lancet; The Lancet Oncology; Association for International Cancer Research, Great Britain; BMBF; Dutch Cancer Society; German Cancer Aid; German National Scholarship Foundation; German Research Foundation

Editorial Board Coordination of clinical trials

Neurooncology (Handling Editor), CNS Oncology, J Neurochemistry (Handling Editor)

http://www.klinikum.uni-heidelberg.de/Studien.108964.0.html Glioblastoma (LKP/PI only and associated preclinical and clinical references)

EORTC 26082: Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779)/RT followed by CCI-779 versus chemo-irradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II study. (Ref. 115) NOA-08: Temozolomid (one week on/one week off) versus Strahlentherapie in der Primärtherapie anaplastischer Astrozytome und Glioblastome bei älteren Patienten: eine randomisierte Phase III-Studie (Methvsalem). (Ref. 114) S039: Enzastaurin (LY317615) Before and Concomitant with Radiation Therapy, Followed by Enzastaurin Maintenance Therapy in Subjects with Newly Diagnosed Glioblastoma – a Multicenter, Open-label, Uncontrolled Phase II Study. (Ref. 56) DIRECTOR: Dose-intensified rechallenge with temozolomide, one week on, one week off in patients with recurrent or progressive glioblastoma. (Ref. 33, 62) UKT-05: Chemoradiotherapy of Newly Diagnosed Glioblastoma with Intensified Temozolomide. (Ref. 66, 117)

4

Anaplastic Glioma (PI/LKP only)

APG-101: A phase II, randomized, open-label, multi-centre study of weekly APG101 + reirradiation versus irradiation in the treatment of patients with first or second progression of glioblastoma; Prüfplannummer: APG101_CD_002. EORTC 26101: Phase II trial exploring the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma. (Ref. 84, 89) NOA-12: A phase I/II, randomized, open-label, multi-centre study of BIBF1120 + reirradiation (R-RT) versus reirradiation in the treatment of patients with first or second progression of glioblastoma. EORTC 26054: Phase III trials comparing no adjuvant chemotherapy versus adjuvant therapy until progression for anaplastic glioma without 1p/19q loss. An EORTC/NCI-C/RTOG intergroup trial. NOA-04: Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide. (Ref. 77) plus > 20 trials in brain tumors and sciatica as investigator or local PI

Heidelberg, October 1st 2014 Prof. Wolfgang Wick, MD

5

Bibliography 1996 1. Wick W, Petersen I, Schmutzler RK, Wolfarth B, Lenartz D, Bierhoff E, Hummerich

J, Muller DJ, Stangl AP, Schramm J, Wiestler OD, von Deimling A. Evidence for a novel tumor suppressor gene on chromosome 15 associated with progression to a metastatic stage in breast cancer. Oncogene 1996;12:973-978

1998 2. Wick W, Wagner S, Kerkau S, Dichgans J, Tonn JC, Weller M. BCL-2 promotes

migration and invasiveness of human glioma cells. FEBS Lett 1998;440:419-424 1999 3. Wick W, Grimmel C, Wagenknecht B, Dichgans J, Weller M. Betulinic acid-induced

apoptosis in glioma cells: a sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. J Pharmacol Exp Ther 1999;289:1306-1312

4. Wick W, Furnari FB, Naumann U, Cavenee WK, Weller M. PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene 1999;18:3936-3943

5. Pohl U, Wick W, Weissenberger J, Steinbach JP, Dichgans J, Aguzzi A, Weller M. Characterization of Tu-2449, a glioma cell line derived from a spontaneous tumor in GFAP-v-src-transgenic mice: comparison with established murine glioma cell lines. Int J Oncol 1999;15:829-834

6. Ständer M, Naumann U, Wick W, Weller M. TGF-β and p21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Cell Tissue Res 1999;296:221-227

2000 7. Platten M, Wick W, Wild-Bode C, Aulwurm S, Dichgans J, Weller M. Transforming

growth factors β1 (TGF-β1) and TGF-β2 promote glioma cell migration via up-regulation of αVβ3 integrin expression. Biochem Biophys Res Commun 2000;268:607-611

8. Schmidt F, Wick W, Herrlinger U, Dichgans J, Weller M. Treosulfan chemotherapy for recurrent malignant glioma. J Neuro-Oncol 2000;49:231-234

9. Von Deimling A, Fimmers R, Schmidt MC, Bender B, Fassbender F, Nagel J, Jahnke

R, Kaskel P, Duerr E-M, Koopmann J, Mainz D, Schild S, Vogel Y, Wick W, Platten M, Müller D, Przkora R, Waha A, Rollbrocker B, Wellenreuther R, Meyer Puttlitz B, Schmidt O, Mollenhauer J, Stangl AP, Lenartz D, von Ammon K, Henson JW, Schramm J, Louis DN, Wiestler OD. Comprehensive allelotype and genetic analysis of 466 human nervous system tumors. J Neuropathol Exp Neurol 2000;59:544-558

10. Wick W, Hochberg F, O’Sullivan J, Goessling A, Hughes A, Cher L. L-Dopa- resistant parkinsonism syndrome following cerebral radiation therapy for neoplasm. Oncol Rep 2000;7:1367-1370

2001 11. Weller M, Streffer J, Wick W, Kortmann RD, Heiss E, Küker W, Meyermann R,

Dichgans J, Bamberg M. Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma: a phase II study. Cancer 2001;91:423-427

12. Wild-Bode C, Weller M, Rimner A, Dichgans J, Wick W. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res 2001;61:2744-2750

13. Platten M, Wild-Bode C, Wick W, Leitlein J, Dichgans J, Weller M. N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits TGF-β release and reduces migration and invasiveness of human malignant glioma cells. Int J Cancer 2001;93:53-61

14. Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, Bähr M, Ohgaki H, Ashkenazi A, Weller M. The soluble decoy receptor-3 is expressed by malignant

6

gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res 2001;61:2759-2765

15. Bähr O, Wick W, Weller M. Modulation of MDR/MRP by wild-type and mutant p53. J Clin Invest 2001;107:643-645

16. Wick W, Grimmel C, Wild-Bode C, Platten M, Arpin M, Weller M. Ezrin-dependent promotion of glioma cell clonogenicity, motility and invasion mediated by BCL-2 and TGF-β2. J Neurosci 2001;21:3360-3368

17. Wild-Bode C, Weller M, Wick W. Molecular determinants of glioma cell migration and invasion. J Neurosurg 2001;94:978-984

18. Naumann U, Kügler S, Wolburg H, Wick W, Rascher G, Schulz JB, Conseiller E, Bähr M, Weller M. Chimeric tumor suppressor 1 (CTS1), a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand. Cancer Res 2001;61:5833-5842

19. Wick W, Platten M, Weller M. Glioma cell invasion: regulation of metalloproteinase activity by TGF-β. J Neuro-Oncol 2001;53:177-185

20. Platten M, Wick W, Wischhusen J, Weller M. N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon-γ (IFN-γ). Br J Pharmacol 2001;134:1279-1284

21. Weller M, Wick W, Platten M. Role of TGF-β in oncogenesis (Editorial). Microscop Res Techn 2001;52:353

22. Platten M, Wick W, Weller M. Malignant glioma biology: role for TGF-β in growth, motility, angiogenesis and immune escape. Microscop Res Techn 2001;52:401-410

2002 23. Wick W, Wick A, Schulz JB, Dichgans J, Rodemann HP, Weller M. Prevention of

irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res 2002;62:1915-1919

24. Wick W, Hermisson M, Küker WM, Kortmann RD, Duffner F, Dichgans J, Bamberg M, Weller M. Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma. A phase II study. J Neuro-Oncol 2002;59:151-155

25. Wick W, Stock J, Seyfried J, Baumgart J, Wüllner U, Weller M. CD95/CD95 ligand-independent potentiation of treosulfan cytotoxicity by a glutathione depleting agent, BSO, in malignant glioma cells in vitro and in vivo. Int J Oncol 2002;21:213-200

26. Herrlinger U, Felsberg J, Küker W, Bornemann A, Plasswilm L, Knobbe CB, Strik H, Wick W, Meyermann R, Dichgans J, Bamberg M, Reifenberger G, Weller M. Gliomatosis cerebri. Molecular pathology and clinical course. Ann Neurol 2002;52:390-399

27. Wick A, Wick W, Waltenberger J, Weller M, Dichgans J, Schulz JB. Hypoxic neuroprotection requires sequential activation of vascular endothelial growth factor receptor and Akt. J Neurosci 2002;22:6401-6407

28. Fulda S*, Wick W*, Weller M, Debatin KM. Smac agonists sensitize for TRAIL/Apo2L- or anticancer drug-induced apoptosis and induce regression of human glioma xenografts. Nat Med 2002;8:808-815 (*geteilte Erstautorenschaft)

29. Nylandsted J, Wick W, Hirt UA, Brand K, Rohde M, Leist M, Weller M, Jäättelä M. Eradication of glioblastoma and breast and colon carcinoma xenografts by Hsp70 depletion. Cancer Res 2002;62:7139-7142

30. Wick W, Weller M. Zur Rolle der Chemotherapie in der Behandlung maligner Gliome. Journal Onkologie 2002;6:26-30

2003 31. Hartmann C, Müller W, Laß U, Stockhammer F, von Eckardstein K, Veelken J,

Jeuken J, Wick W, von Deimling A. No preferential loss of paternal 19q alleles in oligodendroglial tumors. Ann Neurol 2003;54:256-258

7

32. Brötz D, Küker W, Maschke E, Wick W, Dichgans J, Weller M. A prospective trial of mechanical physiotherapy for lumbar disk prolapse. J Neurol 2003 250:746-749

33. Rieger J, Wick W, Weller M. Human malignant glioma cell lines express semaphorins and their receptors, neuropilins and plexins. Glia 2003;42:379-389

34. Naumann U, Schmidt F, Wick W, Frank B, Weit S, Gillissen B, Daniel P, Weller M. Adenoviral natural born killer (NBK) gene therapy of malignant glioma. Hum Gene Ther 2003;14:1235-1246

35. Bähr O, Rieger J, Duffner F, Meyermann R, Weller M, Wick W. P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells. Brain Pathol 2003;13:482-494

2004 36. Naumann U, Wick W, Beschorner R, Meyermann R, Weller M. Expression and

functional activity of osteoprotegerin in human malignant gliomas. Acta Neuropathol 2004;107:17-22

37. Wick W, Steinbach JP, Küker WM, Dichgans J, Bamberg M, Weller M. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 2004;62:2113-2115

38. Wick W, Wick A, Küker W, Dichgans J, Weller M. Intracranial metastatic esthesioneuroblastoma responsive to temozolomide. J Neuro-Oncol 2004;70:73-75

39. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M. SD-208, a novel TGF-β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004;64:7954-7961

40. Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, Weller M. RNA interference targeting TGF-β1,2 enhances NKG2D-mediated anti-glioma immune response, inhibits glioma cell migration and invasiveness and abrogates tumorigenicity in vivo. Cancer Res 2004;64:7596-7603

41. Wick W, Wild-Bode C, Frank B, Weller M. BCL-2-induced glioma cell invasiveness depends on furin-like proteases. J Neurochem 2004;91:1275-1283

42. Wick A, Wick W, Hirrlinger J, Gerhardt E, Dringen R, Dichgans J, Weller M, Schulz JB. Chemotherapy-induced cell death in primary cerebellar granule neurons but not in astrocytes: in vitro paradigm of differential neurotoxicity. J Neurochem 2004;91:1067-1074

43. Wick W, Küker W. Brain edema in neurooncology: radiological assessment and management. Onkologie 2004;27:261-266

44. Wick W. Management unerwünschter Wirkungen der Chemotherapie maligner Glioma. Onkologie Service 2004

45. Naumann U, Wick W, Beschorner R, Meyermann R, Weller M. Reply to Lorenz et al.: Osteoprotegerin in the central nervous system. Acta Neuropathol 2004;107:578 (letter to the editor)

2005 46. Uhl M, Weiler M, Wick W, Jacobs AH, Weller M, Herrlinger U. Migratory neural

stem cells for improved thymidine kinase-based gene therapy of malignant gliomas. Biochem Biophys Res Commun 2005;328:125-129

47. Eyüpoglu IY, Hahnen E, Buslei R, Siebzehnrübl FA, Savaskan NE, Lüders M, Christian Tränkle C, Wick W, Weller M, Fahlbusch R, Blümcke I. Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. J Neurochem 2005;93:992-999

48. Wick W, Weller M. How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. J Clin Oncol 2005;23:4325-4326

49. Koch D, Wick W. Higher dosing of temozolomide? Regression of an anaplastic oligoastrocytoma over more than three years. J Neurooncol 2005,77:219-220

8

50. Große-Hovest L, Wick W, Minoia R, Weller M, Rammensee H-G, Brem G, Jung G. A „supra-agonistic“, bispecific single chain antibody purified from the serum of cloned, transgenic cows induces T-cell mediated killing of glioblastoma cells in vitro and in vivo. Int J Cancer 2005;117:1060-1064

51. Wick W, Menn O, Meisner C, Steinbach J, Hermisson M, Tatagiba M, Weller M. Pharmacotherapy of epileptic seizures in brain tumor patients: who, when, why and how long? Onkologie 2005;28:391-398

52. Tabatabai G, Bähr O, Möhle R, Eyüpoglu IY, Boehmler A, Wischhusen J, Dichgans J, Blümcke I, Weller M, Wick W. Lessons from the bone marrow: how malignant glioma cells attract adult hematopoietic stem cells. Brain 2005;128:2200-2211

53. Weiler M, Bähr O, Hohlweg U, Naumann U, Rieger J, Huang H, Tabatabai G, Krell HW, Ohgaki H, Weller M, Wick W. Bcl-xL: time-dependent dissociation between modulation of apoptosis and invasiveness in human malignant glioma cells. Cell Death Differ 2006;13:1156-1169

54. Weller M, Steinbach JP, Wick W. Temozolomide, a milestone in the pharmacotherapy of brain tumors. Future Oncol 2005;1:747-754

2006 55. Steinbach JP, Blaicher H-P, Herrlinger U, Wick W, Nägele T, Meyermann R,

Tatagiba M, Bamberg M, Dichgans J, Karnath H-O, Weller M. Surviving glioblastoma for more than 5 years: the patients’ perspective. Neurology 2006;66:239-42

56. Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Kaina B, Weller M. MGMT and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 2006;96:766-76

57. Eyüpoglu IY, Hahnen E, Tränkle C, Savaskan NE, Siebzehnrübl FA, Buslei R, Lemke D, Wick W, Fahlbusch R, Blümcke I. Experimental therapy of malignant gliomas using the inhibitor of class I histone deacetylase MS-275. Mol Cancer Ther 2006;5:1248-55

58. Roos WP, Batista LFZ, Naumann S, Wick W, Weller M, Menck CFM, Kaina B. Apoptosis in glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 2007;26:186-97

59. Tabatabai G, Frank B, Möhle R, Weller M, Wick W. Irradiation and hypoxia promote homing of hematopoietic progenitor cells towards gliomas by TGF-β-dependent HIF-1α-mediated induction of CXCL12. Brain 2006;129:2426-2435

60. Grassmé H, Jin J, Wilker B, von Kürthy G, Wick W, Weller M, Möröy T, Gulbins E. Regulation of pulmonary Pseudomonas aeruginosa infection by the transcriptional repressor Gfi1. Cellular Microbiology 2006;8:1096-1105

61. Naumann U, Bähr O, Wolburg H, Altenberend S, Wick W, Liston P, Ashkenazi A, Weller M. Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice. Gene Therapy 2007;14:147-61

62. Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann R-D, Steinbach JP, Hundsberger T, Wick W, Meyermann R, Sommer C, Bamberg M, Reifenberger G, Weller M. UKT-03 phase II trial of CCNU plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma. J Clin Oncol 2006;24:4412-4417

63. Wick W, Naumann U, Weller M. Transforming growth factor-β: a molecular target for the future therapy of glioblastoma. Curr Pharm Design 2006;12:341-349

64. Wick W, von Deimling A, Grabenbauer GG, Westphal M. Anaplastische Gliome Standards und neue Entwicklungen in Diagnostik und Therapie. Der Onkologe 2006;12:508-518

65. Wick W, Kaufman A. Glioblastoma: what’s ischemia got to do with it? (Editorial) Neurology 2006;67:1540-41

2007 66. Mittelbronn M, Capper D, Bunz B, Dietz K, Goeppert B, Ajaaj R, Tabatabai G,

9

Stubenvoll F, Schlaszus H, Merseburger AS, Becker R, Freudenstein D, Wick W, Weller M, Meyermann R, Simon P. De novo erythropoietin receptor (EPO-R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survival. Neuropathol Appl Neurobiol 2007;33:299-307

67. Tabatabai G, Frank B, Wick A, Lemke D, von Kürthy G, Obermüller U, Heckl S, Christ G, Weller M, Wick W. Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann Neurol 2007;61:153-161

68. Vollmann H, Wölfel S, Ohneseit P, Stransky E, Vonthein R, Wick W, Meyermann R, Simon P. Differential expression of Egr1 and activation of microglia following irradiation in the rat brain. Strahlenther und Onkol 2007;183:248-255

69. Tran T-T, Uhl M, Ma JY, Janssen L, Sriram V, Aulwurm S, Kerr I, Lam A, Webb HK, Kapoun AM, Kizer DE, McEnroe G, Hart B, Axon J, Murphy A, Chakravarty S, Dugar S, Protter AA, Higgins LS, Wick W, Weller M, Wong DH. Inhibiting TGF-β signaling restores immune surveillance in the SMA-560 glioma model. Neuro Oncol 2007;9:259-270

70. Burkhardt I, Tritschler F, Opitz CA, Frank B, Weller M, Wick W. Pirfenidone inhibits TGF-β expression in malignant glioma cells. Biochem Biophys Res Commun 2007;354;342-347

71. Rieger J, Frank B, Weller M, Wick W. Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand. Cell Physiol Biochem 2007;20:23-34

72. Roth P, Mittelbronn M, Meyermann R, Wick W, Weller M. Malignant glioma cells counteract anti-tumor immune responses through expression of lectin-like transcript-1. Cancer Res 2007;67:3540-3544

73. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, Weller M, Wick.W. Efficacy and tolerability of Temozolomide in an one week on/one week off regimen in patients with recurrent glioma. J Clin Oncol 2007;25:3357-3361

74. Platten M, Opitz C, Kohlhof P, Hegenbart U, Ho AD, Wick W. Painful neuropathy due to intraneural metastases in a patient with acute myeloid leukaemia. Neurology 2007;69:707

75. Wick W, Platten M. Brain tumor-related edema. Rivista medica 2007;13:1-3

76. Hacke W, Oertel W, Wick W, Hartung H-P, Ringleb PA, Diener, H-C. Die großen klinischen Studien – Evidenzbasierte Medizin in der Deutschen Neurologie. Akt Neurol 2007;34:386-389

77. Opitz CA, Wick W, Steinman L, Platten M. Tryptophan degredation in autoimmune disease. Cell Mol Life Sci 2007;64:2542-63

2008

78. Murat A, Migliavacca E, Gorlia T, Lambiv W, Shay T, Hamou M-F, de Tribolet N, Regli L, Wick W, Kouwenhoven M, Hainfellner JA, Heppner FL, Dietrich P-Y, Zimmer Y, Cairncross G, Janzer R-C, Domany E, Delorenzi M, Stupp R, Hegi ME. Stem cell-related „self-renewal signature“ and high EGFR expression are associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008;26:3015-24

79. Wick W, Stupp R, Beule A-C, Bromberg J, Wick A, Ernemann U, Platten M, Marosi C, Mason W, van den Bent M, Weller M, Rorden C, Karnath H-O. A novel tool to analyse MRI recurrence patterns in glioblastoma. Neuro-oncol, 2008;10:1019-24

80. Tabatabai G, Herrmann C, Frank B, Möhle R, Mittelbronn M, Weller M, Wick W. Glioma cell-mediated upregulation of CD62E on endothelial cells contributes to glioma tropism of adult hematopoietic progenitor cells. Brain 2008;131:2579-95

10

81. Rieger J, Maurer G, Frank B, Tabatabai G, Weller M, Wick W. Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL . J Neurochem 2008;106:2436-48

82. Happold C, Roth P, Ernemann U, Wick W, Weller M, Schmidt F. Anticoagulation for radiation-induced neurotoxicity revisited. J Neurooncol 2008;90:357-61

83. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR. Correlation of MGMT Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity. J Clin Oncol 2008;26:4189-99

84. Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, Wick W. Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma. Clin Cancer Res 2008;14:2900-2908

85. Wick A, Wick W. Aktuelle Studienkonzepte in der Primär- und Rezidivtherapie. Onkologie heute 2008;4:23-31

86. Eisele G, Roth P, Wick W, Weller M. MGMT in der klinischen Praxis. Onkologie heute 2008;4:32-39

2009

87. Maurer GD, Tritschler I, Adams B, Tabatabai G, Wick W, Stupp R, Weller M. Cilengitide modulates attachment, invasiveness and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro-oncol 2009;11:747-56

88. Wick A, Pascher C, Wick W, Jauch T, Weller M, Bogdahn U, Hau P. Rechallenge with temozolomide in recurrent gliomas. J Neurol 2009;256:734-41

89. Broetz D, Hahn U, Maschke E, Wick W, Kueker W, Weller M. Lumbar disk prolapse: Response to mechanical physiotherapy in the absence of changes in magnetic resonance imaging. Report of 11 cases. NeuroRehabilitation 2008;23:289-94

90. Glas M, Happold C, Rieger J, Wiewrodt D, Bähr O, Steinbach JP, Wick W, Kortmann R-D, Reifenberger G, Weller M, Herrlinger U. Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 2009;27:1257-61

91. Happold C, Roth P, Wick W, Steinbach JP, Linnebank M, Weller M, Eisele G. ACNU-based chemotherapy for recurrent glioma in the temozolomide era. J Neurooncol 2009;92:45-8

92. Opitz CA, Litzenburger UM, Lutz C, Lanz TV, Tritschler I, Köppel A, Tolosa E, Hoberg M, Anderl J, Aicher WK, Weller M, Wick W, Platten M. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 2009;27:909-19

93. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann R, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, v. Deimling A, Reifenberger G, Weller M, for the Neurooncology Working Group (NOA) of the German Cancer Society. NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide. J Clin Oncol 2009;27:5874-80

94. Tritschler I, Wick W, Keski-Oja H, Weller M. Modulation of TGF-βactivity by latent TGF-β-binding protein 1 in human malignant glioma cells. Int J Cancer 2009 125:530-40

95. Ronellenfitsch MW, Burger MC, Brucker DP, Tritschler F, Rieger J, Wick W, Weller

M, Steinbach JP. Antagonism of the serine/threonine kinase mTOR selectively mediates metabolic effects of EGFR inhibition and protects human malignant glioma cells from hypoxia-induced cell death. Brain 2009 132:1509-22

11

96. Lanz TV, Opitz CA, Ho PP, Agrawal A, Weller M, Steinman L, Wick W, Platten M.

Mouse mesenchymal stem cells suppress antigen-specific TH-cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1). Stem Cells and Dev 2010; 19(5):657-68

97. Gramatzki D, Pantazis G, Schittenhelm J, Tabatabai G, Köhle C, Wick W, Schwarz M, Weller M, Tritschler I. Aryl Hydrocarbon receptor inhibition down-regulates TGF-β/Smad pathway in human glioblastoma cells. Oncogene 2009;28:2593-605

98. Brötz D, Maschke E, Burkard S, Engel C, Mänz C, Ernemann U, Wick W, Weller M. Is there a role for benzodiazepines in the management of acute sciatica? Pain 2010;149:470-5

99. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Mawrin

C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken J, Wesseling P, Reifenberger G, von Deimling A. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation, grade and age: A study of 1010 diffuse gliomas. Acta Neuropathol 2009;118:469-474

100. Wick W, Platten M, Weller M. New temozolomide regimens for the treatment of glioma. Neuro-oncol 2009:11:69-79

101. Wick A, Weller M, Wick W. Molecular defined chemotherapies and targeted therapies for malignant glioma. Onkopipeline 2008;1:11-17

102. Weller M, Wick W. Current therapeutic standards in malignant glioma. Onkopipeline 2008;1:36-37

103. Platten M, Vogt-Schaden M, Löw S, Bendszus M, Weller M, Wick W. Therapy of Primary CNS Lymphomas. Onkopipeline 2009;2:2-10

104. Weiler M, Whyte L, Hodecker S, Wick W. Challenges in Diagnosis and Treatment of Recurrent Glioma: Novel Compounds and Therapeutic Use of Stem Cells. Onkopipeline 2009;2:23-29

105. Schlegel U, Korfel A, Thiel E, Wick W, Kortmann R, Deckert M, Schackert G. Primäre ZNS-Lymphome. Onkologe 2009;15:211-17

106. Wick W, Seidel C, Wick A, Platten M. Neurooncology in elderly patients. Nervenheilkunde 2009;28:304-9

107. Wick W, Weller M. Classification and management of anaplastic gliomas. Curr Opin Neurol 2009;22(6):650-6

2010

108. Weiler M, Hartmann C, Wiewrodt D, Herrlinger U, Bähr OR, Meyermann R, Bamberg M, Tatagiba M, von Deimling A, Weller M, Wick W. Phase II trial of radiochemotherapy with daily concomitant and adjuvant intensified (one week on / one week off) temozolomide plus indomethacin in newly diagnosed glioblastoma: UKT-05. Int J Rad Biol Phys 2010;77:670-6

109. Wick W, Puduvalli VK, Chamberlain M, van den Bent MJ, Carpentier A, Cher L, Mason W, Weller M, Hong S, Musib L, Leipa A, Thornton D, Fine H. Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma: a phase III study. J Clin Oncol 2010;28:1168-74

110. Wick A, Schäfer N, Dörner N, Schemmer D, Platten M, Bendszus M, Wick W. Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome. J Neuroonc 2010;97:157-8

111. Rieken S, Gaiser T, Mohr A, Welzel T, Witt O, Kulozik AE, Wick W, Debus J, Combs SE. Outcome and prognostic factors after radiation therapy for desmoplastic medulloblastoma. BMC Cancer 2010 doi:10.1186/1471-2407-10-450

12

112. Wen PY, Macdonald DA, Reardon DA, Cloughesy TM, Sorensen AG, Galanis E, DeGroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated Response Assessment Criteria For High-Grade Gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. J Clin Oncol 2010;28:1963-72

113. Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol 2011;13:353-61

114. Berger B, Capper D, Lemke D, Pfenning P-N, Platten M, Weller M, von Deimling A, Wick W, Weiler M. Defective p53 antiangiogenic signaling in glioblastoma. Neuro Oncol 2010;12:894-907

115. Wick A, Dörner N, Schäfer N, Hofer S, Schemmer D, Weller M, Platten M, Bendszus M, Wick W. Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol 2011;69:586-92

116. Tabatabai G, Hasenbach K, Herrmann C, Maurer G, Möhle R, Marini P, Grez M, Wick W, Weller M. Glioma tropism of lentivirally transduced hematopoietic progenitor cells. Int J Oncol 2010;36:1409-17

117. Soffietti R, Baumert B, Bello L, von Deimling A, Duffau H, Frénay M, Grisold W, Grant R, Graus F, Hoang-Xuan K, Klein M, Melin B, Rees J, Siegal T, Smits A, Stupp R, Wick W. Guidelines on management of lowgrade gliomas: report of an EFNS-EANO* task force. Eur J Neurol 2010;17:1124-33

118. Roth P, Junker M, Tritschler I, Mittelbronn M, Dombrowski Y, Breit SN, Tabatabai G, Wick W, Weller M, Wischhusen J. GDF-15 Contributes to Proliferation and Immune Escape of Malignant Gliomas. Clin Cancer Res 2010;16: 3851-9

119. Heiland S, Wick W, Bendszus M. Perfusion MRI for parametric response maps in tumors: is it really that easy? J Clin Oncol 2010;28:e591

120. Rieken S, Mohr A, Habermehl D, Welzel T, Lindel K, Witt O, Kulozik AE, Wick W, Debus J, Combs SE. Outcome and prognostic factors of radiation therapy for medulloblastoma. Int J Radiat Oncol Biol Phys 2010;10:450

121. Weller M, Stupp R, Reifenberger G, Brandes A, van den Bent MJ, Wick W, Hegi M. MGMT promoter methylation in malignant gliomas: molecular neuropathology ready for personalized medicine? Nat Rev Neurol 2010;6:39-51

122. Wick W, Weller M, van den Bent M, Stupp R. Avastin and recurrent malignant gliomas: a European perspective. J Clin Oncol 2010;28:188-189

123. Roth P, Wick W, Weller M. Steroids in neurooncology: actions, indications, side effects. Curr Opinion Neurol 2010;23:597-602

124. Tabatabai G, Stupp R, van den Bent MJ, Hegi ME, Tonn JC, Wick W, Weller M. Molecular Diagnostics of Gliomas: the Clinical Perspective. Acta Neuropathol 2010;120:585-592

125. Ronellenfitsch MW, Steinbach JP, Wick W. Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives. Targeted Oncology 2010;5:183-191

126. Weller M, Wick W, Hegi ME, Stupp R, Tabatabai G. Should biomarkers be used to design personalized medicine for the treatment of glioblastoma? Future Oncol 2010;6:1406-1414

127. Wick W, Weller M. Anaplastic glioma: Neuropathology, molecular diagnostics and current study concepts. Nervenarzt 2010;81(8):928-30, 932-5. doi: 10.1007/s00115-010-2956-1

2011

13

128. Opitz CA, Litzenburger UM, Opitz U, Sahm F, Ochs K, Lutz C, Wick W, Platten M. The Indoleamine-2,3-dioxygenase (IDO) inhibitor 1-Methyl-D-tryptophan upregulates IDO1 in human cancer cells. Plos One 2011;6(5):e19823

129. Combs SE, Kieser M, Rieken S, Habermehl D, Jäkel O, Haberer T, Nikoghosyan A, Haselmann R, Unterberg A, Wick W, Debus J. Randomized Phase II study Evaluating a Carbon Ion Boost applied after Combined Radiochemotherapy with Temozolomide versus a Proton Boost after Radiochemotherapy with Temozolomide in Patients with Primary Glioblastoma - The CLEOPATRA Trial. BMC Cancer 2010;10:478

130. Grauer O, Pascher C, Hartmann C, Zeman F, Weller M, Proescholdt M, Brawanski A, Pietsch T, Wick W, Bogdahn U, Hau P. Neoadjuvant temozolomide and 13-cis retinoic acid treatment in patients with anaplastic gliomas (RNOP-05). J Neurooncol 2011;104:801-9

131. Combs SE, Burkholder I, Edler L, Rieken S, Habermehl D, Jäkel O, Haberer T, Haselmann R, Unterberg A, Wick W, Debus J. Carbon Ion Radiotherapy versus Fractionated Stereotactic Radiotherapy in Patients with Recurrent or Progressive Gliomas: The CINDERELLA Trial. BMC Cancer 2010;10:533

132. Radbruch A, Bendszus M, Wick W, Heiland S. Pitfalls in perfusion MRI in brain tumors. Clinical Neuroradiology 2010;20:183-4

133. Eisele G, Roth P, Hasenbach K, Aulwurm S, Wolpert F, Tabatabai G, Wick W, Weller M. APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro Oncol 2011;13:155-64

134. Seidel C, Dörner N, Osswald M, Wick A, Platten M, Bendszus M, Wick W. Does age matter? - An MRI study on peritumoral edema in newly diagnosed primary glioblastoma. BMC Cancer 2011;11:127

135. Combs SE, Rieken S, Wick W, Abdollahi A, von Deimling A, Debus J, Hartmann C. Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back? Radiat Oncol 2011 13;6:115

136. Hofer S, Elandt K, Greil R, Hottinger AF, Huber U, Lemke D, Marosi C, Ochsenbein A, Pichler J, Roelcke U, Weder P, Zander T, Wick W, Weller M. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol 2011;50:630-5

137. Combs SE, Edler L, Burkholder I, Rieken S, Habermehl D, Jäkel O, Haberer T, Unterberg A, Wick W, Debus J, Haselmann R. Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: the MARCIE trial. BMC Cancer 2010;10:615

138. Reifenberger G, Hentschel B, Felsberg J, Schackert G, Simon M, Schnell O, Westphal

M, Wick W, Pietsch T, Loeffler M, Weller M, for the German Glioma Network. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 2012;131(6):1342-50. doi: 10.1002/ijc.27385

139. Brockschmidt A, Trost D, Peterziel H, Zimmermann K, Pfenning P, Ehrler M, Grassmann H, Waha A, Stabenow D, Brockschmidt F, Hoischen A, Kalla C, Waha A, Seifert G, Knolle P, Latz E, Wick W, Hans V, Pfeifer A, Angel P, Weber R. KIAA1797/FOCAD encodes a novel focal adhesion protein with tumor suppressor function in gliomas. Brain 2012;135:1027-41

140. Ahmadi R, Stockhammer F, Becker N, Hohlen K, Misch M, Christians A, Dictus C, Herold-Mende C, Capper D, Unterberg A, von Deimling A, Wick W, Hartmann C. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. J Neurooncol 2012 109(1):15-22. doi: 10.1007/s11060-012-0863-y

141. Lemke D, Pfenning PN, Sahm F, Klein AC, Kempf T, Warnken U, Schnölzer M, Tudoran R, Weller M, Platten M, Wick W. Costimulatory Protein 4IgB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness. Clin Cancer Res 2012;18:105-17

14

142. Hertenstein A, Litzenburger U, Schumacher T, Opitz CA, Falk CS, Serafini T, Wick W, Platten M. Suppression of human CD4+ T cell activation by 3,4-dimethoxycinnamonyl-anthranilic acid (tranilast) is mediated by CXCL9 and CXCL10. Biochem Pharmacol 2011;82:632-41

143. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehman I, von Deimling A, Wick W, Platten M. An endogenous ligand of the human aryl hydrocarbon receptor promotes tumor formation. Nature 2011;478:197-203

144. Nagel AM, Bock M, Hartmann C, Gerigk L, Neumann JO, Weber MA, Bendszus M, Radbruch A, Wick W, Schlemmer HP, Semmler W, Biller A. The Potential of Relaxation-Weighted Sodium Magnetic Resonance Imaging as Demonstrated on Brain Tumors. Invest Radiol 2011;46:539-547

145. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010;120:707-18

146. Radbruch A, Lutz K, Wiestler B, Bäumer P, Heiland S, Wick W, Bendszus M. Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria. Neuro Oncol 2012;14:222-9. Dec 6 2011

147. Wick W, Weller M, Weiler M, Batchelor T, Yung AWK, Platten M. Pathway inhibition: Emerging molecular targets for treating glioblastoma. Neuro Oncol 2011;13:566-79

148. Weller M, Wick W, von Deimling A. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas. Glia 2011;59:1200-4

149. Wick W, Wick A, Weiler M, Weller M. Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence. Current Neurology and Neuroscience Reports 2011;11:305-12.

150. Weller M, Wick W. "Nanomania" ante portas of neurooncology? J Neurooncol 2010 Dec 25

151. Weller M, Wick W. Are we ready to demystify age in glioblastoma? Or does older age matter in glioblastoma? Neuro Oncol 2011;13: 365-366

152. Weller M, Platten M, Roth P, Wick W. Geriatric neuro-oncology: from mythology to biology. Curr Opin Neurol 2011;24:599-604

153. Wick W, Weller M. Trabedersen to target transforming growth factor-beta: when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142). Neuro Oncol 2011;13:559-60; author reply 561-2

154. Tabatabai G, Wick W, Weller M. Stem cell-mediated gene therapies for malignant gliomas: a promising targeted therapeutic approach? Discov Med 2011;11:529-36

155. Wick W. Anaplastic gliomas: an emerging entity. Eur J Cancer 2011;47 Suppl 3:S357-8

156. Brandes AA, Franceschi E, Gorlia T, Wick W, Jacobs AH, Baumert BG, van den Bent M, Weller M, Stupp R; On behalf of European Organisation for Research and Treatment of Cancer Brain Tumour Group. Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma. Eur J Cancer 2012;48(6):896-903. EPub 2011 Nov 23

157. Wick W, Blaes J, Weiler M. mTORC 2:1 for Chemotherapy Sensitization in Glioblastoma. Cancer Discov 2011;1:475-6.

15

2012

158. Platten M, Litzenburger U, Wick W. The aryl hydrocarbon receptor in tumor immunity. OncoImmunology 2012 May 1;1(3):396-397.

159. Platten M, Opitz C, Wick W. The aryl hydrocarbon receptor as a promoter of malignant glioma. Cell Cycle 2012;15;11(4):643-4

160. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper M, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M, for the Neurooncology Working Group (NOA) of the German Cancer Society Chemotherapy versus radiotherapy for malignant astrocytoma in the elderly. Lancet Oncol 2012,13(7):707-15

161. Weiler M, Pfenning P-N, Thiepold A-L, Blaes J, Jestaedt L, Gronych J, Dittmann LM, Berger B, Jugold M, Kosch M, Combs SE, von Deimling A, Weller M, Bendszus M, Platten M, Wick W. Suppression of Proinvasive RGS4 by mTOR Inhibition Optimizes Glioma Treatment. Oncogene Epub 2012 May 7; 2013 Feb 28;32(9):1099-109

162. Beynon C, Hoffmann T, Wick W, Unterberg AW, Kiening KL. Stereotactic brainstem biopsy in a patient with coagulopathy of unclear etiology: case report. Minim Invasive Neurosurg 2011;54:268-70

163. Christians A, Hartmann C, Benner A, Meyer J, von Deimling A, Weller M, Wick W, Weiler M. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. Plos One 2012;7(3):e33449

164. Happold C, Roth P, Wick W, Schmidt N, Florea A-M, Reifenberger G, Weller M. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. J Neurochem 2012;122(2):444-55

165. Seidel C, Hentschel B, Simon M, Schnell O, Heese O, Tatagiba M, Krex D, Reithmeier T, Kowoll A, Weller M, Wick W. A comprehensive analysis of vascular complications in 3889 glioma patients from the German Glioma Network. J Neurol 2013;260(3):847-55 Epub 2012 Oct 27

166. Wiestler B, Claus R, Hartlieb SA, Schliesser MG, Weiss EK, Hielscher T, Platten M, Dittmann LM, Meisner C, Felsberg J, Happold C, Simon M , Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Grimm C, Weichenhan D, Tews B, Reifenberger G, Capper D, Müller W, Plass C, Weller M, Wick W for the Neurooncology Working Group (NOA) of the German Cancer Society. Malignant gliomas of elderly patients have a distinct molecular profile: An analysis of the NOA-08 study collective. Neurooncol 2013;15(8):1017-26

167. Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, v. Deimling A, Gramatzki D, Westphal

M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M. IDH1 mutations determine the prognostic versus predictive value of MGMT promoter methylation in malignant gliomas. Neurology 2013;81(17):1515-22

168. Combs SE, Edler L, Rausch R, Welzel T, Wick W, Debus J. Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma. Acta Oncol 2013;52(1):147-52 EPub 2012 Jun 11.

16

169. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E, Tönjes M, Sill M, Bender S, Kool M, Zapatka M, Becker N, Zucknick M, Hielscher T, Liu XY, Fontebasso AM, Ryzhova M, Albrecht S, Jacob K, Wolter M, Ebinger M, Schuhmann MU, van Meter T, Frühwald MC, Hauch H, Pekrun A, Radlwimmer B, Niehues T, von Komorowski G, Dürken M, Kulozik AE, Madden J, Donson A, Foreman NK, Drissi R, Fouladi M, Scheurlen W, von Deimling A, Monoranu C, Roggendorf W, Herold-Mende C, Unterberg A, Kramm CM, Felsberg J, Hartmann C, Wiestler B, Wick W, Milde T, Witt O, Lindroth AM, Schwartzentruber J, Faury D, Fleming A, Zakrzewska M, Liberski PP, Zakrzewski K, Hauser P, Garami M, Klekner A, Bognar L, Morrissy S, Cavalli F, Taylor MD, van Sluis P, Koster J, Versteeg R, Volckmann R, Mikkelsen T, Aldape K, Reifenberger G, Collins VP, Majewski J, Korshunov A, Lichter P, Plass C, Jabado N, Pfister SM. Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. Cancer Cell 2012;22:425-37

170. Ott M, Litzenburger UM, Sahm F, Rauschenbach KJ, Tudoran R, Hartmann C, Marquez VE, von Deimling A, Wick W, Platten M. Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase. PLoS One 2012;7:e47663

171. Radbruch A, Lutz K, Bäumer P, Wiestler B, Weiler M, Röthke M, Schlemmer HP, Heiland S, Wick W, Bendszus M. Differentiation of Glioblastoma and Primary CNS Lymphoma Using Susceptibility Weighted Imaging. European Journal of Radiology 2013;82(3):552-6

172. Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R, Marosi C, Zielinski C, Mehta MP, Winkler F, Wick W, von Deimling A. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 2012;123:205-22

173. Weller M, Stupp R, Hegi M, Wick W. Individualized targeted therapy for glioblastoma: fact or fiction? Cancer J 2012;18:40-4

174. Platten M, Wick W, van den Eynde B. Tryptophan catabolism in cancer: Beyond IDO and tryptophan depletion. Cancer Res 2012 72(21):5435-40

175. Weller M, Stupp R, Wick W. Epilepsy meets Cancer: when, why, and what to do about it? Lancet Oncol 2012;13:e375-82

176. Galanis E, Wu W, Cloughesy T, Lamborn K, Mann B, Wen PY, Reardon DA, Wick W, Macdonald D, Armstrong TS, Weller M, Vogelbaum M, Colman H, Sargent DJ, van den Bent MJ, Gilbert M, Chang S. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol 2012;13:e196-204.

177. Reardon DA, Perry JR, Brandes AA, Jalali R, Wick W. Advances in malignant glioma drug discovery. Expert Opin Drug Discov 2011;6:739-53

178. Wick W, Weller M for the NOA-08 Study Group. Response to Chamberlain and Fiorentina et al. on The NOA-08 randomized phase III trial of chemotherapy versus radiotherapy for malignant astrocytoma in the elderly. Lancet Oncol 2012 (Letter to the Editor)

179. Weiler M, Wick W. Molecular predictors of outcome in low-grade glioma. Current Opinion in Neurology 2012;25:767-73.

180. Weller M, Stupp R, Hegi ME, van den Bent M, Tonn JC, Sanson M, Wick W, Reifenberger G. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients inclinical practice. Neuro Oncol 2012;14 Suppl 4:iv100-8

181. Platten M, Wick W. Treatment of brain tumor patients: Hyperthermia, hyperbaric oxygenation, electric fields or nanoparticles. Nervenarzt 2012;83:982-7.

182. Laperriere N, Weller M, Stupp R, Perry JR, Brandes AA, Wick W, van den Bent MJ. Optimal management of elderly patients with glioblastoma. Cancer Treat Rev 2013;39(4):350-7 EPub 2012 Jun 19.

2013

17

183. Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma—are we there yet? Neuro Oncol 2013;15:4-27.

184. RTOG 9802: good wines need aging. van den Bent MJ, Baumert B, Jaeckle K, Wick W. J Clin Oncol 2013;31(5):653-4

185. Radbruch A, Wiestler B, Sahm F, Heiland S, Röthke M, Wick W, Schlemmer H-P, Bendszus M. Quantitative susceptibility mapping differentiation between blood depositions and calcifications in patients with glioblastoma. Plos One 2013;8(3):e57924

186. Seystahl K, Wiestler B, Hundsberger T, Happold C, Wick W, Weller M, Wick A. Bevacizumab Alone or in Combination with Irinotecan in Recurrent WHO Grade II and Grade III Gliomas. Eur Neurol 2013;69:95-101.

187. Sahm F, Opitz CA, Radlwimmer B, von Deimling A, Bode HB, Wick W, Platten M. The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress. Cancer Res 2013;73(11):3225-34

188. Domhan S, Schwager C, Wei Q, Muschal S, Sommerer C, Morath C, Wick W, Maercker C, Debus J, Zeier M, Huber PE, Abdollahi A. Deciphering the systems biology of mTOR inhibition by integrative transcriptome analysis. Curr Pharm Des 2013 Mar 19

189. Wick W, Steinbach JP, Platten M, Hartmann C, Wenz F, von Deimling A, Shei P, Moreau-Donnet V, Stoffregen C, Combs SE. Enzastaurin Before and Concomitant with Radiation Therapy, Followed by Enzastaurin Maintenance Therapy, in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation. Neuro Oncol 2013;15(10):1405-12

190. Goeppert B, Schmidt CR, Geiselhart L, Dutruel C, Capper D, Renner M, Vogel MN, Zachskorn C, Zinke J, Campos B, Schmezer P, Popanda O, Wick W, Weller M, Meyermann R, Schittenhelm J, Harter PN, Simon P, Weichert W, Schirmacher P, Plass C, Mittelbronn M. Differential Expression of the Tumor Suppressor A Kinase Anchor Protein 12 (AKAP12) in Human Diffuse and Pilocytic Astrocytomas Is Regulated by Promoter Methylation. J Neuropath Exp Neurol 2013;72(10):933-41

191. Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, Platten M, Weller M, Wick W. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 2013;126(3):443-51

192. Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Curr Treat Options Oncol 2013;14(4):505-13

193. Lanz TV, Becker S, Osswald M, Bittner S, Schuhmann MK, Opitz CA, Gaikwad S, Wiestler B, Litzenburger UM, Sahm F, Ott M, Iwantscheff S, Grabitz C, Mittelbronn M, von Deimling A, Winkler F, Meuth SG, Wick W, Platten M. Protein kinase Cβ as a therapeutic target stabilizing blood-brain barrier disruption in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2013;110(36):14735-40

194. Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, Dill D, Dippel E, Eigentler T, Feyer P, Follmann M, Frerich B, Ganten MK, Gärtner J, Gutzmer R, Hassel J, Hauschild A, Hohenberger P, Hübner J, Kaatz M, Kleeberg UR, Kölbl O, Kortmann RD, Krause-Bergmann A, Kurschat P, Leiter U, Link H, Loquai C, Löser C, Mackensen A, Meier F, Mohr P, Möhrle M, Nashan D, Reske S, Rose C, Sander C, Satzger I, Schiller M, Schlemmer HP, Strittmatter G, Sunderkötter C, Swoboda L, Trefzer U, Voltz R, Vordermark D, Weichenthal M, Werner A, Wesselmann S, Weyergraf AJ, Wick W, Garbe C, Schadendorf D.M alignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". J Dtsch Dermatol Ges. 2013;11 Suppl 6:1-116, 1-126

195. Ochs K, Sahm F, Opitz CA, Lanz TV, Oezen I, Couraud PO, von Deimling A, Wick W, Platten M. Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma. J Neuroimmunol 2013;265(1-

18

2):106-16

196. Reinert C, Kremmler L, Burock S, Bogdahn U, Wick W, Gleiter CH, Koller M, Hau P. Quantitative and qualitative analysis of study-related patient information sheets in randomised neuro-oncology phase III-trials. Eur J Cancer 2013 Oct 5

197. Lutz K, Wiestler B, Graf M, Bäumer P, Floca R, Schlemmer HP, Heiland S, Wick W, Bendszus M, Radbruch A. Infiltrative patterns of glioblastoma: Identification of tumor progress using apparent diffusion coefficient histograms. J Magn Reson Imaging 2013 Sep 30

198. Tabatabai G, Stupp R, Wick W, Weller M. Malignant astrocytoma in elderly patients: where do we stand? Curr Opin Neurol 2013;26(6):693-700

199. Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DT, Kool M, Northcott PA, Wiestler B, Böhmer K, Meyer J, Mawrin C, Hartmann C, Mittelbronn M, Platten M, Brokinkel B, Seiz M, Herold-Mende C, Unterberg A, Schittenhelm J, Weller M, Pfister S, Wick W, Korshunov A, von Deimling A. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol 2013;126(6):907-15.

200. Wick W, Wick A, Platten M. Good maths is needed to understand CMV data in glioblastoma. Int J Cancer 2013 Nov 18

201. Han K, Ren M, Wick W, Abrey L, Das A, Jin J, Reardon DA. Progression-free survival as a surrogate endpoint for hazard ratio and median overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro Oncology 2013 Dec 12.

202. Kickingereder P, Wiestler B, Sahm F, Deike K, Heiland S, Roethke M, Schlemmer H-P, Wick W, Bendszus M, Radbruch A. Multiparametric differentiation of primary CNS lymphoma and atypical glioblastoma using diffusion-, perfusion-, and susceptibility-weighted MRI. Radiology in press

203. Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, Bunse L, Solecki G,

Eichwald V, Jugold M, Hodecker SC, Osswald M, Meisner C, Hielscher T, Rübmann P, Pfenning P-N, Ronellenfitsch M, Kempf T, Schnölzer M, Abdollahi A, Lang F, Bendszus M, von Deimling A, Winkler F, Weller M, Vajkoczy P, Platten M, Wick W. The mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad Sci USA 2013 Dec 23

204. Wick W, Wick A, Platten M. Challenging (the) CMV data in glioblastoma. Neuro Oncol 2013 Dec 18.

205. Wick W, Platten M, Reifenberger G, Weller M. Molecular Subtyping of Anaplastic Gliomas. Neurology in press (letter)

2014

206. Nowosielski M, Wiestler B, Goebel G, Hutterer M, Schlemmer HP, Stockhammer G, Wick W, Bendszus M, Radbruch A. Progression types after anti-angiogenic therapy are related to outcome in recurrent glioblastoma. Neurology April 11 2014

207. Weller M, Wick W. Neuro-oncology in 2013: Improving outcome in newly diagnosed malignant glioma. Nat Rev Neurol 2014;10:68-70.

208. Blaes J, Weiler M, Sahm F, Hentschel B, Osswald M, Czabanka M, Thomé CM, Schliesser MG, Pusch S, Luger S, Winkler F, Radbruch A, Jugold M, Simon M, Steinbach JP, Schackert G, Tatagiba M, Westphal M, Tonn JC, Gramatzki D, Pietsch

T, Hartmann C, Glimm H, Vajkoczy P, von Deimling A, Platten M, Weller M, Wick W. NDRG1 prognosticates the natural course of disease in WHO grade II glioma. J Neurooncol 2014;117:25-32

19

209. Eisele G*, Wick A*, Eisele A-C, Clement PM, Tonn J-C, Tabatabai G, Ochsenbein A, Schlegel U, Neyns B, Krex D, Simon M, Nikkhah G, Picard M, Stupp R, Wick W, Weller M. Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. J Neurooncol 2014;117:141-145

210. Wiestler B, Radbruch A, Osswald M, Combs SE, Jungk C, Winkler F, Bendszus M, Unterberg A, Platten M, Wick W, Wick A. Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma. J Neuroonc 2014;117:85-92

211. Wick W, Platten M. CMV infection and glioma, a highly controversial concept struggling in the clinical arena. Neuro Oncol 2014;16:332-3.

212. Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G, Soffietti R, Wick W, for the European Association for Neuro-Oncology (EANO) Task Force on Malignant GliomaEANO Guideline on the Diagnosis and Treatment of Malignant Glioma. The Lancet Oncology accepted

213. Kickingereder P, Sahm F, Wiestler B, Röthke M, Heiland S, Schlemmer H-P, Wick W, von Deimling A, Bendszus M, Radbruch A.Evaluation of microvascular permeability with dynamic contrast-enhanced MRI for the differentiation of primary CNS lymphoma and glioblastoma: radiologic-pathologic correlation. Am J Neuroradiol 2014 April 10

214. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T. Bevacizumab Plus Radiotherapy/Temozolomide for Newly Diagnosed Glioblastoma. New Engl J Med 2014; 370:709-722.

215. Platten M, Ochs K, Lemke D, Opitz C, Wick W. Microenvironmental clues for glioma immunotherapy. Curr Neurol Neurosci Rep 2014;14:440

216. Zhu Z, Khan MA, Weiler M, Jonas Blaes J, Jestaedt L, Zou P, Gronych J, Bernhardt O, Korshunov A, Lichter P, Radlwimmer B, Heiland S, Bendszus M, Wick W, Liu H-K. Targeting Self-renewal in High-Grade Brain Tumors Leads to Loss of Brain Tumor Stem Cells and Prolonged Survival. Cell Stem Cells 2014 in press

217. Reifenberger G, Weber RG, Riehmer V, Kaulich K, Willscher E, Wirth H, Gietzelt J, Hentschel B, Westphal M, Simon M, Schackert G, Schramm J, Matschke J, Sabel MC, Gramatzki D, Felsberg J, Hartmann C, Steinbach JP, Schlegel U, Wick W, Radlwimmer B, Pietsch T, Tonn JC, von Deimling A, Binder H, Weller M, Loeffler M; for the German Glioma Network. Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. Int J Cancer 2014 Mar 11.

218. Letter to the Editor. Chinot O, Wick W, Cloughesy T. New Engl J Med 2014;

219. Wick W, Weller M, van den Bent M, Sanson M, Weiler M, von Deimling A, Plass C, Hegi M, Platten M, Reifenberger G. MGMT testing in neurooncology - A paradigm for prospects and challenges of biomarker-based treatment decisions. Nat Rev Neurol 2014; in press

220. Litzenburger UM, Opitz CA, Sahm F, Rauschenbach KJ, Trump S, Winter M, Ott M, Ochs K, Lutz C, Liu X, Anastasov N, Lehmann I, Höfer T, von Deimling A, Wick W, Platten M. Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget. 2014 Jan 20.

221. Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, Keil M, Balss J, Rauschenbach K, Grabowska AK, Vogler I, Diekmann J, Trautwein N, Eichmüller S, Okun J, Stefanovic S, Riemer AB, Sahin U, Friese M, Beckhove P, von Deimling A, Wick W, Platten M (2014). A vaccine targeting mutant IDH1 induces antitumor immunity. Nature accepted